Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.

Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I.

J Clin Oncol. 1997 Jan;15(1):61-8.

PMID:
8996125
2.

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.

Nysom K, Holm K, Lipsitz SR, Mone SM, Colan SD, Orav EJ, Sallan SE, Olsen JH, Hertz H, Jacobsen JR, Lipshultz SE.

J Clin Oncol. 1998 Feb;16(2):545-50.

PMID:
9469339
3.

Does anthracycline administration by infusion in children affect late cardiotoxicity?

Levitt GA, Dorup I, Sorensen K, Sullivan I.

Br J Haematol. 2004 Feb;124(4):463-8.

PMID:
14984495
4.

Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.

Vandecruys E, Mondelaers V, De Wolf D, Benoit Y, Suys B.

J Cancer Surviv. 2012 Mar;6(1):95-101. doi: 10.1007/s11764-011-0186-6. Epub 2011 Jun 1.

5.

Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study.

Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID.

Cancer. 2003 Apr 15;97(8):1991-8.

6.

Cardiac function in Wilms' tumor survivors.

Sorensen K, Levitt G, Sebag-Montefiore D, Bull C, Sullivan I.

J Clin Oncol. 1995 Jul;13(7):1546-56.

PMID:
7602343
7.

Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.

Rammeloo LA, Postma A, Sobotka-Plojhar MA, Bink-Boelkens MT, Berg A, Veerman AJ, Kamps WA.

Med Pediatr Oncol. 2000 Jul;35(1):13-9.

PMID:
10881002
8.

Low anthracyclines doses-induced cardiotoxicity in acute lymphoblastic leukemia long-term female survivors.

Amigoni M, Giannattasio C, Fraschini D, Galbiati M, Capra AC, Madotto F, Cesana F, Jankovic M, Masera G, Mancia G.

Pediatr Blood Cancer. 2010 Dec 15;55(7):1343-7. doi: 10.1002/pbc.22637.

PMID:
20589666
9.

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.

Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD.

J Clin Oncol. 2005 Apr 20;23(12):2629-36.

PMID:
15837978
10.

Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.

Feig SA, Ames MM, Sather HN, Steinherz L, Reid JM, Trigg M, Pendergrass TW, Warkentin P, Gerber M, Leonard M, Bleyer WA, Harris RE.

Med Pediatr Oncol. 1996 Dec;27(6):505-14.

PMID:
8888809
11.

Low-dose anthracyclines in childhood Acute Lymphoblastic Leukemia (ALL): no cardiac deterioration more than 20 years post-treatment.

Brouwer CA, Gietema JA, van den Berg MP, Bink-Boelkens MT, Elzenga NJ, Haaksma J, Kamps WA, Vonk JM, Postma A.

J Cancer Surviv. 2007 Dec;1(4):255-60. doi: 10.1007/s11764-007-0031-0. Epub 2007 Sep 27.

PMID:
18648960
12.

Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy.

Leger K, Slone T, Lemler M, Leonard D, Cochran C, Bowman WP, Bashore L, Winick N.

Pediatr Blood Cancer. 2015 Jan;62(1):123-7. doi: 10.1002/pbc.25206. Epub 2014 Aug 30.

PMID:
25176022
13.

Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.

Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Henkel JM, Franco VI, Cushman LL, Asselin BL, Clavell LA, Athale U, Michon B, Laverdière C, Schorin MA, Larsen E, Usmani N, Sallan SE; Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium.

Pediatrics. 2012 Dec;130(6):1003-11. doi: 10.1542/peds.2012-0727. Epub 2012 Nov 19.

14.

Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.

Feijen EA, Leisenring WM, Stratton KL, Ness KK, van der Pal HJ, Caron HN, Armstrong GT, Green DM, Hudson MM, Oeffinger KC, Robison LL, Stovall M, Kremer LC, Chow EJ.

J Clin Oncol. 2015 Nov 10;33(32):3774-80. doi: 10.1200/JCO.2015.61.5187. Epub 2015 Aug 24.

15.

Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline.

Sung RY, Huang GY, Shing MK, Oppenheimer SJ, Li CK, Li CK, Lau J, Yuen MP.

Int J Cardiol. 1997 Aug 8;60(3):239-48.

PMID:
9261634
16.

Exposure to anthracyclines during childhood causes cardiac injury.

Lipshultz SE.

Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. Review.

PMID:
16781284
17.
18.

Cardiac functions by myocardial performance index and QT dispersion in survivors of childhood lymphoblastic leukaemia.

Gulen H, Kazanci E, Mese T, Uzunkaya D, Erbay A, Tavli V, Vergin C.

Minerva Pediatr. 2007 Apr;59(2):107-13.

PMID:
17404560
19.

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD.

Lancet Oncol. 2010 Oct;11(10):950-61. doi: 10.1016/S1470-2045(10)70204-7. Epub 2010 Sep 16.

20.

Late cardiac damage of anthracycline therapy for acute lymphoblastic leukemia in childhood.

Prestor VV, Rakovec P, Kozelj M, Jereb B.

Pediatr Hematol Oncol. 2000 Oct-Nov;17(7):527-40.

PMID:
11033728

Supplemental Content

Support Center